Results 201 to 210 of about 14,491 (226)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology
PURPOSE Weight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association with baseline characteristics.
Barend J Sikkema +7 more
semanticscholar +1 more source
PURPOSE Weight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association with baseline characteristics.
Barend J Sikkema +7 more
semanticscholar +1 more source
BMJ Case Reports
Management of cancer during pregnancy requires careful consideration of risks and benefits from maternal and fetal perspectives. For advanced lung adenocarcinomas, with no targetable driver mutations, there is evidence-based guidance on the use of ...
Florence T H Wu +3 more
semanticscholar +1 more source
Management of cancer during pregnancy requires careful consideration of risks and benefits from maternal and fetal perspectives. For advanced lung adenocarcinomas, with no targetable driver mutations, there is evidence-based guidance on the use of ...
Florence T H Wu +3 more
semanticscholar +1 more source
Cancer Medicine
The ALINE trial demonstrated the superiority of alectinib over platinum‐based chemotherapy in resected Anaplastic Lymphoma Kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC).
Qiran Wei +3 more
semanticscholar +1 more source
The ALINE trial demonstrated the superiority of alectinib over platinum‐based chemotherapy in resected Anaplastic Lymphoma Kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC).
Qiran Wei +3 more
semanticscholar +1 more source
Cancer Research
Background Alectinib is a central nervous system (CNS)-penetrant, oral, inhibitor of ALK-fusion proteins that has demonstrated durable responses in adults with ALK-positive non-small cell lung cancer.
François Doz +18 more
semanticscholar +1 more source
Background Alectinib is a central nervous system (CNS)-penetrant, oral, inhibitor of ALK-fusion proteins that has demonstrated durable responses in adults with ALK-positive non-small cell lung cancer.
François Doz +18 more
semanticscholar +1 more source
Journal of Clinical Oncology
8006 Background: ALINA (NCT03456076) is a global, open-label, phase 3, randomized trial evaluating the efficacy and safety of adjuvant alectinib versus chemotherapy in patients with resected stage IB (≥4 cm)–IIIA, ALK+ NSCLC.
M. Nishio +18 more
semanticscholar +1 more source
8006 Background: ALINA (NCT03456076) is a global, open-label, phase 3, randomized trial evaluating the efficacy and safety of adjuvant alectinib versus chemotherapy in patients with resected stage IB (≥4 cm)–IIIA, ALK+ NSCLC.
M. Nishio +18 more
semanticscholar +1 more source
Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Journal of Medicinal Chemistry, 2021Yuan Sun, Zhe-Sheng Chen, Jin-Yi Xu
exaly